<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group>
<journal-title>PLoS ONE</journal-title></journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PONE-D-13-05525</article-id>
<article-id pub-id-type="doi">10.1371/journal.pone.0064325</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Clinical research design</subject><subj-group><subject>Cohort studies</subject><subject>Prospective studies</subject></subj-group></subj-group><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Pathology</subject><subj-group><subject>General pathology</subject><subj-group><subject>Biomarkers</subject></subj-group></subj-group></subj-group></subj-group><subj-group><subject>Nutrition</subject></subj-group><subj-group><subject>Ophthalmology</subject><subj-group><subject>Pediatric ophthalmology</subject><subject>Retinal disorders</subject></subj-group></subj-group><subj-group><subject>Pediatrics</subject><subj-group><subject>Pediatric ophthalmology</subject></subj-group></subj-group><subj-group><subject>Public health</subject><subj-group><subject>Child health</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Early Nutrition and Weight Gain in Preterm Newborns and the Risk of Retinopathy of Prematurity</article-title>
<alt-title alt-title-type="running-head">NutWtGain ROP</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>VanderVeen</surname><given-names>Deborah K.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Martin</surname><given-names>Camilia R.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mehendale</surname><given-names>Reshma</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Allred</surname><given-names>Elizabeth N.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Dammann</surname><given-names>Olaf</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Leviton</surname><given-names>Alan</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><collab xlink:type="simple">for the ELGAN Study Investigators</collab><xref ref-type="fn" rid="fn1"><sup>¶</sup></xref></contrib>
</contrib-group>
<aff id="aff1"><label>1</label><addr-line>Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America</addr-line></aff>
<aff id="aff2"><label>2</label><addr-line>Department of Neonatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America</addr-line></aff>
<aff id="aff3"><label>3</label><addr-line>Neuroepidemiology Unit, Boston Children’s Hospital, Boston, Massachusetts, United States of America</addr-line></aff>
<aff id="aff4"><label>4</label><addr-line>Department of Neurology, Harvard Medical School, Boston, Massachusetts, United States of America</addr-line></aff>
<aff id="aff5"><label>5</label><addr-line>Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, United States of America</addr-line></aff>
<aff id="aff6"><label>6</label><addr-line>Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, Massachusetts, United States of America</addr-line></aff>
<aff id="aff7"><label>7</label><addr-line>Perinatal Neuroepidemiology Unit, Hannover Medical School, Hannover, Germany</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Vavvas</surname><given-names>Demetrios</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><addr-line>Massachusetts Eye &amp; Ear Infirmary, Harvard Medical School, United States of America</addr-line></aff>
<author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">deborah.vanderveen@childrens.harvard.edu</email></corresp>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn>
<fn fn-type="con"><p>Conceived and designed the experiments: DKV CRM ENA OD AL. Performed the experiments: DKV CRM ENA OD AL. Analyzed the data: DKV RM CRM ENA OD AL. Contributed reagents/materials/analysis tools: DKV RM CRM ENA OD AL. Wrote the paper: DKV RM CRM ENA OD AL.</p></fn>
<fn id="fn1" fn-type="other"><p>¶ Investigators of the ELGAN Study are provided in the Acknowledgments.</p></fn>
</author-notes>
<pub-date pub-type="collection"><year>2013</year></pub-date>
<pub-date pub-type="epub"><day>29</day><month>5</month><year>2013</year></pub-date>
<volume>8</volume>
<issue>5</issue>
<elocation-id>e64325</elocation-id>
<history>
<date date-type="received"><day>4</day><month>2</month><year>2013</year></date>
<date date-type="accepted"><day>14</day><month>4</month><year>2013</year></date>
</history>
<permissions>
<copyright-year>2013</copyright-year>
<copyright-holder>Vanderveen et al</copyright-holder><license xlink:type="simple"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions>
<abstract><sec>
<title>Objective</title>
<p>To identify nutritional and weight gain limitations associated with retinopathy of prematurity (ROP) severity among very preterm newborns.</p>
</sec><sec>
<title>Patients and Methods</title>
<p>1180 infants &lt;28 weeks GA at birth with ROP examination results were grouped and analyzed by quartile of weekly total calorie, carbohydrate, protein, and lipid intake, as well as growth velocity between postnatal days 7 and 28 (adjusted for GA and birth weight Z-score). ROP was categorized by development of no, mild (&lt;prethreshold), type 2, or type 1 ROP, as well as markers of ROP severity including stage 3 ROP, zone 1 disease, and plus disease. Associations between nutritional intake and ROP severity were compared.</p>
</sec><sec>
<title>Results</title>
<p>Greater risk for Type 1 ROP (risk/95% confidence intervals) was found for infants with lowest quartile receipt of lipids (2.1/1.1, 3.8), total calories (2.2/1.4, 3.6), and carbohydrates (1.7/1.1, 2.9). Development of zone 1 ROP was associated with lipid or total calorie intake in the lowest quartile, and development of stage 3 ROP was associated with lowest quartile of total calorie intake. Growth velocity in the lowest quartile was associated with increased risk of any ROP, including type 1 ROP.</p>
</sec><sec>
<title>Conclusion</title>
<p>The risk of developing severe ROP in extremely premature infants might be reduced by improving nutritional support, specifically targeting lipids and total calories, and perhaps by improving weight gain.</p>
</sec></abstract>
<funding-group><funding-statement>This research was supported by cooperative agreements with the National Institute of Neurological Diseases and Stroke (5U01NS040069-05 and 2R01NS040069-06A2), a grant from the National Eye Institute (1R21EY019253-01), and a grant from the National Institute of Child Health and Human Development (5P30HD018655-28). The funders did not have any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="7"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>Retinopathy of prematurity (ROP), a neovascular disease of the retina found in very premature infants, can result in life-long visual limitations. Identifying the antecedents of ROP provides additional information on relevant pathogenic mechanisms involved and has the potential to help reduce the occurrence of this disease and its consequences. <xref ref-type="bibr" rid="pone.0064325-Heidary1">[1]</xref>.</p>
<p>Early nutritional support is a critical part of optimizing growth and development in the premature infant, including normal retinal vascularization. Insulin-like growth factor (IGF)-1 is important for normal infant growth <xref ref-type="bibr" rid="pone.0064325-Engstrm1">[2]</xref>–<xref ref-type="bibr" rid="pone.0064325-Pirazzoli1">[4]</xref> and retinal vascularization, <xref ref-type="bibr" rid="pone.0064325-Hellstrm1">[5]</xref>–<xref ref-type="bibr" rid="pone.0064325-Smith1">[8]</xref> and is regulated by total caloric and protein intake. <xref ref-type="bibr" rid="pone.0064325-Engstrm1">[2]</xref> Lipid emulsions are an important part of nutritional support; omega-3 long chain polyunsaturated fatty acids have been shown to suppress inflammatory factors and contribute to antiangiogenic and neuroprotective mechanisms in the retina. <xref ref-type="bibr" rid="pone.0064325-Drenckpohl1">[9]</xref>–<xref ref-type="bibr" rid="pone.0064325-Connor1">[13]</xref> Early weight gain is an important marker of nutritional status, and poor postnatal weight gain has been associated with an increased risk of severe ROP. <xref ref-type="bibr" rid="pone.0064325-Allegaert1">[14]</xref>–<xref ref-type="bibr" rid="pone.0064325-FortesFilho1">[17]</xref> Algorithms have been developed that employ postnatal weight gain and IGF levels to predict development of severe ROP. <xref ref-type="bibr" rid="pone.0064325-Lfqvist1">[18]</xref>, <xref ref-type="bibr" rid="pone.0064325-Lfqvist2">[19]</xref>.</p>
<p>Premature infants enrolled in the ELGAN (<italic>e</italic>xtremely <italic>l</italic>ow <italic>g</italic>estational <italic>a</italic>ge <italic>n</italic>ewborn) Study had assessments of nutritional support (carbohydrate, protein, lipids, and total calories) and weight measurements during the first 28 days of life. We evaluated the relationships between components of early nutritional support and weight gain with markers of ROP severity in this at-risk population.</p>
</sec><sec id="s2" sec-type="materials|methods">
<title>Patients and Methods</title>
<sec id="s2a">
<title>Sample</title>
<p>The ELGAN Study, a prospective cohort study designed to identify characteristics and exposures that increase the risk of structural and functional neurologic disorders, enrolled 1506 extremely low gestational age newborns (birth between 23 and 27 6/7 weeks of gestation) at one of 14 participating institutions between 2002–2004. <xref ref-type="bibr" rid="pone.0064325-OShea1">[20]</xref> The enrollment and consent processes were approved by the individual institutional review boards, and research conducted according to the principles expressed in the Declaration of Helsinki. Written informed consent was obtained from the parents and/or legal guardians of all infants enrolled in the study.</p>
<p>Of these newborns, 1187 had their weight recorded on days 7 and 28, as well as nutrition information collected on days selected for analysis (days 3, 7, 14, and 21). The gestational age, birth weight, and other perinatal characteristics of 1064 of these 1187 infants are presented elsewhere. <xref ref-type="bibr" rid="pone.0064325-Chen1">[21]</xref> Results of retinal examinations were available for 1180 of these infants. The enrollment and consent processes were approved by the individual institutional review boards.</p>
</sec><sec id="s2b">
<title>Infant Characteristics</title>
<p>Gestational age (GA) estimates were based on a hierarchy of the quality of available information with estimates based on the dates of embryo retrieval or intrauterine insemination or fetal ultrasound before the 14<sup>th</sup> week of gestation (62%) as the most desirable. Next most desirable in sequential order were estimates based on a fetal ultrasound at 14 or more weeks of gestation (29%), last menstrual period without fetal ultrasound (7%), and GA recorded in the log of the NICU (1%).</p>
</sec><sec id="s2c">
<title>Nutrition Data</title>
<p>Detailed nutritional data were collected daily for the first 7 postnatal days, then weekly on days 14, 21, and 28. <xref ref-type="bibr" rid="pone.0064325-Martin1">[22]</xref> Type and volume of intravenous solutions (including composition of parenteral nutrition) as well as type and volume of enteral feedings (including caloric additives) were routinely recorded. All nutritional practice variables summarize nutritional intake from both parenteral and enteral routes.</p>
<p>Nutrient information was calculated for the macronutrients protein, carbohydrates, and fats. These totals were calculated by multiplying the daily total volume of the diet by the macronutrient content as specific on the nutritional label for all formula types and nutritional additives, such as powdered proteins or fat oils. For breast milk, we calculated nutritional intake using values for mature milk (Ross Neonova system, version 4.5, 1999) since by 14 days the composition of preterm milk and term milk are similar. Although human milk composition can be very dynamic, it was not feasible in this study to capture the composition of every breast milk sample provided to the infants.</p>
<p>Total kilocalories per day were divided by the birth weight until the birth weight was surpassed, then by the weight on the day the nutritional information was collected. The final units for the macronutrient calculations were kcals/kg/day. For analysis, we categorized the mean total nutrient (g/kg/day) and mean total calories (kcal/kg/day) on each of four selected days (3, 7, 14 and 21) into quartiles.</p>
</sec><sec id="s2d">
<title>Weight Change</title>
<p>Body weight was measured each day in the first postnatal week, then on days 14, 21 and 28. The rate in growth is expressed as g/kg/day. Because ELGANs tend to lose weight during the first postnatal week <xref ref-type="bibr" rid="pone.0064325-Ehrenkranz1">[23]</xref> our measure of weight gain was calculated for the interval between days 7 and 28 [((wt28-wt7)/wt7)/(28-7) 1000×g/kg/day]. We categorized this measure of weight gain into quartiles.</p>
</sec><sec id="s2e">
<title>Eye Examinations</title>
<p>Retinal examinations were performed by ophthalmologists experienced in ROP screening. Participating ophthalmologists helped prepare a manual and data collection form, and then participated in efforts to minimize observer variability. Definitions of terms were those accepted by the International Committee for Classification of ROP. <xref ref-type="bibr" rid="pone.0064325-The1">[24]</xref> In keeping with guidelines, <xref ref-type="bibr" rid="pone.0064325-Screeningexaminationofprematureinfantsforretinopathyof1">[25]</xref>–<xref ref-type="bibr" rid="pone.0064325-Screeningexaminationofprematureinfantsforretinopathyof2">[26]</xref> the first ophthalmologic examination was within the 31<sup>st</sup> to 33<sup>rd</sup> post-menstrual week. Follow-up exams were as clinically indicated until normal vascularization began in zone III.</p>
<p>For purposes of discussion, prethreshold ROP is defined as any ROP in zone 1, stage 2 ROP in zone 2 with plus disease, or stage 3 ROP in zone 2 with or without plus disease. Prethreshold ROP is designated as type 1 or type 2 ROP, <xref ref-type="bibr" rid="pone.0064325-Early1">[27]</xref> as follows:</p>
<p>Type 1 ROP:</p>
<list list-type="bullet"><list-item>
<p>zone I, any stage ROP with plus disease;</p>
</list-item><list-item>
<p>zone I, stage 3 ROP without plus disease; or</p>
</list-item><list-item>
<p>zone II, stage 2 or 3 ROP with plus disease.</p>
</list-item></list>
<p>Type 2 ROP</p>
<list list-type="bullet"><list-item>
<p>zone I, stage 1 or 2 ROP without plus disease or</p>
</list-item><list-item>
<p>zone II, stage 3 ROP without plus disease.</p>
</list-item></list>
<p>During the study period, criteria for treatment of ROP varied, due to participation in the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial, or due to subsequent changes in treatment recommendations <xref ref-type="bibr" rid="pone.0064325-Early1">[27]</xref>–<xref ref-type="bibr" rid="pone.0064325-Fielder1">[28]</xref>. We did not evaluate need to treat as a separate indicator of severity, since some eyes of infants in the ELGAN study received treatment for high-risk prethreshold or type 1 ROP, while others received treatment only when threshold ROP developed. Threshold ROP was defined as 5 contiguous or 8 cumulative clock hours of stage 3 ROP with plus disease in zone 1 or 2, so all cases previously designated as threshold or near threshold ROP are included in the current classification of type 1 ROP.</p>
<p>In this analysis, we categorized ROP severity in four ways: no ROP, mild ROP (&lt;prethreshold), type 2 ROP, and type 1 ROP. Additional markers of severity were noted as≥stage 3 ROP, zone I disease, and presence of plus disease. The comparison groups in these analyses include infants with no or mild ROP.</p>
</sec><sec id="s2f">
<title>Statistical Analyses</title>
<p>We evaluated two hypotheses. First, infants who received nutrition (<italic>i.e</italic>., protein, carbohydrate, fat and total calories) in the lowest quartile are not at increased risk of any measure of ROP severity. Second, infants in the lowest quartile of weight gain are not at increased risk of any indicator of ROP severity.</p>
<p>We evaluated these hypotheses in two ways. One set of analyses was characterized by logistic regression models of each level of severity compared to the referent group of children who did not have any ROP. To account for the possibility that infants born at a particular hospital are more like each other than like infants born at other hospitals, a hospital cluster term was included in all of these models. <xref ref-type="bibr" rid="pone.0064325-Begg1">[29]</xref>.</p>
<p>Because each level of severity is mutually exclusive and each is appropriately compared to the same referent group of infants without any ROP, we also created multinomial (aka polytomous or polychotomous) logistic regression models. <xref ref-type="bibr" rid="pone.0064325-Dubin1">[30]</xref>, <xref ref-type="bibr" rid="pone.0064325-Liang1">[31]</xref> Multinomial models do not allow a cluster term to be included.</p>
<p>All models adjusted for gestational age category (23–24, 25–26, 27 weeks), and birth weight Z-score category (&lt;−2, ≥ −2 to&lt;−1, ≥ −1 to 0, ≥0). We calculated odds ratios (and 95% confidence intervals) with the aid of the logistic regression models.</p>
<p>By and large, the two sets of analyses provided similar findings. For economy of space we present only results obtained with the multinomial models.</p>
</sec></sec><sec id="s3">
<title>Results</title>
<p>Of the 1180 infants studied, 876 (74%) developed ROP (<xref ref-type="table" rid="pone-0064325-t001">Table 1</xref>). Thirty percent (359/1180) developed prethreshold ROP, and 13% (156/1180) developed Type 1 ROP. ROP≥ stage 3 developed in 345 infants; zone 1 disease was present in 89 infants.</p>
<table-wrap id="pone-0064325-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0064325.t001</object-id><label>Table 1</label><caption>
<title>Sample description.</title>
</caption><alternatives><graphic id="pone-0064325-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0064325.t001" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">No</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Enrolled</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">1506</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Weight measured: on days 7 and 28</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">1187</td>
<td align="left" rowspan="1" colspan="1">319</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Nutrition information available<xref ref-type="table-fn" rid="nt101">*</xref></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">1187</td>
<td align="left" rowspan="1" colspan="1">0</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ROP diagnoses available</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">1180</td>
<td align="left" rowspan="1" colspan="1">7</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">No ROP (this is the referent group)</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">304</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Therapy</td>
<td align="left" rowspan="1" colspan="1">Mild</td>
<td align="left" rowspan="1" colspan="1">517</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">oriented</td>
<td align="left" rowspan="1" colspan="1">Type 2</td>
<td align="left" rowspan="1" colspan="1">203</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Type 1</td>
<td align="left" rowspan="1" colspan="1">156</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Stage</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">260</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">271</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">≥3</td>
<td align="left" rowspan="1" colspan="1">345</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Zone</td>
<td align="left" rowspan="1" colspan="1">III</td>
<td align="left" rowspan="1" colspan="1">52</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1">765</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">89</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Plus disease</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">131</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt101"><label>*</label><p>collected on selected days: 3, 7, 14, and 21.</p></fn></table-wrap-foot></table-wrap>
<p><xref ref-type="fig" rid="pone-0064325-g001">Figure 1</xref> shows the distribution of mean total nutrients and calories received on days of life 3, 7, 14 and 21. Not only was the median amount of carbohydrates received by children who had no ROP higher than those who developed ROP, but the more severe the ROP, the lower the median. A similar pattern was seen for median total fat, and mean total calories, but not for median total protein. In contrast to the linear relationships between the levels of some nutrients and ROP severity, no such pattern was seen between weight gain between days 7 and 28 and ROP severity.</p>
<fig id="pone-0064325-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0064325.g001</object-id><label>Figure 1</label><caption>
<title>Box and whiskers displays of total carbohydrate, protein, and fat (g/kg/day), total calories (kcal/kg/day), and growth velocity (g/kg/day) among children classified by ROP severity.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0064325.g001" position="float" xlink:type="simple"/></fig>
<p><xref ref-type="table" rid="pone-0064325-t002">Table 2</xref> displays the risk of ROP for infants whose receipt of each nutrient or calorie intake was in the lowest quartile, adjusted for gestational age and birth weight Z-score. Increased risk of type 1 ROP was found for infants in the lowest quartile for carbohydrate, fat, and total calorie intake. Increased risk of≥stage 3 ROP was found for infants in the lowest quartile of total calorie intake, and increased risk of zone 1 ROP was found for infants in the lowest quartile of fat or total calorie intake. Receipt of low amounts of protein was not associated with appreciably increased risk of any ROP severity.</p>
<table-wrap id="pone-0064325-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0064325.t002</object-id><label>Table 2</label><caption>
<title>The risks (and 95% confidence intervals) of the ROP level identified on the left among infants whose receipt of the nutrient or calories at the top of each column was in the lowest quartile relative to the risk among children whose receipt was in the top 3 quartiles.</title>
</caption><alternatives><graphic id="pone-0064325-t002-2" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0064325.t002" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td colspan="2" align="left" rowspan="1">Retinopathyof prematurity</td>
<td colspan="4" align="left" rowspan="1">Lowest quartile</td>
</tr>
<tr>
<td colspan="2" align="left" rowspan="1"/>
<td align="left" rowspan="1" colspan="1">CHO</td>
<td align="left" rowspan="1" colspan="1">Protein</td>
<td align="left" rowspan="1" colspan="1">Fat</td>
<td align="left" rowspan="1" colspan="1">Calories</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Therapy</td>
<td align="left" rowspan="1" colspan="1">Mild</td>
<td align="left" rowspan="1" colspan="1">1.5 (0.99, 2.2)</td>
<td align="left" rowspan="1" colspan="1">0.9 (0.6, 1.2)</td>
<td align="left" rowspan="1" colspan="1"><bold>1.7 (1.1, 2.6)</bold></td>
<td align="left" rowspan="1" colspan="1">1.0 (0.7, 1.5)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">oriented</td>
<td align="left" rowspan="1" colspan="1">Type 2</td>
<td align="left" rowspan="1" colspan="1"><bold>1.9 (1.2, 3.0)</bold></td>
<td align="left" rowspan="1" colspan="1">0.9 (0.6, 1.4)</td>
<td align="left" rowspan="1" colspan="1"><bold>2.9 (1.8, 4.8)</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>1.7 (1.1, 2.7)</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Type 1</td>
<td align="left" rowspan="1" colspan="1"><bold>1.7 (1.1, 2.9)</bold></td>
<td align="left" rowspan="1" colspan="1">1.1 (0.7, 1.8)</td>
<td align="left" rowspan="1" colspan="1"><bold>2.8 (1.7, 4.7)</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>2.2 (1.4, 3.6)</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Stage</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">1.1 (0.7, 1.8)</td>
<td align="left" rowspan="1" colspan="1">1.1 (0.8, 1.6)</td>
<td align="left" rowspan="1" colspan="1">1.1 (0.7, 1.9)</td>
<td align="left" rowspan="1" colspan="1">0.8 (0.5, 1.3)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1"><bold>1.8 (1.1, 2.7)</bold></td>
<td align="left" rowspan="1" colspan="1">0.7 (0.4, 1.00)</td>
<td align="left" rowspan="1" colspan="1"><bold>2.3 (1.4, 3.6)</bold></td>
<td align="left" rowspan="1" colspan="1">1.2 (0.8, 1.9)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">≥3</td>
<td align="left" rowspan="1" colspan="1">2.0 (0.3, 3.1)</td>
<td align="left" rowspan="1" colspan="1">1.0 (0.7, 1.5)</td>
<td align="left" rowspan="1" colspan="1">3.2 (2.0, 5.0)</td>
<td align="left" rowspan="1" colspan="1"><bold>2.1 (1.4, 3.2)</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Zone</td>
<td align="left" rowspan="1" colspan="1">III</td>
<td align="left" rowspan="1" colspan="1">1.3 (0.6, 2.8)</td>
<td align="left" rowspan="1" colspan="1">1.8 (0.9, 3.3)</td>
<td align="left" rowspan="1" colspan="1">1.1 (0.5, 2.9)</td>
<td align="left" rowspan="1" colspan="1">1.1 (0.5, 2.4)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1"><bold>1.6 (1.1, 2.4)</bold></td>
<td align="left" rowspan="1" colspan="1">0.8 (0.6, 1.1)</td>
<td align="left" rowspan="1" colspan="1"><bold>2.1 (1.4, 3.2)</bold></td>
<td align="left" rowspan="1" colspan="1">1.3 (0.9, 1.8)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">1.8 (0.99, 3.2)</td>
<td align="left" rowspan="1" colspan="1">1.4 (0.8, 2.5)</td>
<td align="left" rowspan="1" colspan="1"><bold>2.6 (1.4, 4.6)</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>2.2 (1.2, 3.8)</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Plus</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">1.1 (0.8, 1.7)</td>
<td align="left" rowspan="1" colspan="1">1.2 (0.8, 1.8)</td>
<td align="left" rowspan="1" colspan="1">1.4 (0.9, 2.0)</td>
<td align="left" rowspan="1" colspan="1">1.5 (0.98, 2.2)</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt102"><p>These have been adjusted for gestational age and birth weight Z-score. <bold>Bolded</bold> odds ratios are significant at the 0.05 level.</p></fn></table-wrap-foot></table-wrap>
<p>Unlike <xref ref-type="table" rid="pone-0064325-t002">Table 2</xref>, <xref ref-type="table" rid="pone-0064325-t003">Table 3</xref> shows the three lower quartiles for growth velocity, which provided an opportunity to see if a dose-response characterized the findings. Weight gain in the lowest quartile was associated with increased risk of all stages of ROP, including type 1ROP. Less limited weight gains were not associated with increased risk of any severity level of ROP.</p>
<table-wrap id="pone-0064325-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0064325.t003</object-id><label>Table 3</label><caption>
<title>The risks (and 95% confidence intervals) of the ROP level identified on the left among infants classified by the quartile of their weight gain between days 7 and 28 relative to the risk among children whose weight gain was in the highest quartile.</title>
</caption><alternatives><graphic id="pone-0064325-t003-3" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0064325.t003" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td colspan="2" align="left" rowspan="1"/>
<td colspan="3" align="left" rowspan="1">Growth velocity quartile</td>
</tr>
<tr>
<td colspan="2" align="left" rowspan="1">Retinopathy of prematurity</td>
<td align="left" rowspan="1" colspan="1">Lowest</td>
<td align="left" rowspan="1" colspan="1">Low middle</td>
<td align="left" rowspan="1" colspan="1">Hi middle</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Therapy</td>
<td align="left" rowspan="1" colspan="1">Mild</td>
<td align="left" rowspan="1" colspan="1"><bold>1.9 (1.2, 3.0)</bold></td>
<td align="left" rowspan="1" colspan="1">1.3 (0.8, 1.9)</td>
<td align="left" rowspan="1" colspan="1">1.3 (0.9, 2.0)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">oriented</td>
<td align="left" rowspan="1" colspan="1">Type 2</td>
<td align="left" rowspan="1" colspan="1"><bold>2.0 (1.2, 3.5)</bold></td>
<td align="left" rowspan="1" colspan="1">1.2 (0.7, 2.0)</td>
<td align="left" rowspan="1" colspan="1">0.9 (0.5, 1.6)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Type 1</td>
<td align="left" rowspan="1" colspan="1"><bold>1.9 (1.1, 3.5)</bold></td>
<td align="left" rowspan="1" colspan="1">0.8 (0.5, 1.5)</td>
<td align="left" rowspan="1" colspan="1">0.8 (0.5, 1.5)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Stage</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1"><bold>1.9 (1.1, 3.1)</bold></td>
<td align="left" rowspan="1" colspan="1">1.3 (0.8, 2.1)</td>
<td align="left" rowspan="1" colspan="1">1.2 (0.8, 1.9)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1"><bold>1.8 (1.1, 3.0)</bold></td>
<td align="left" rowspan="1" colspan="1">1.2 (0.7, 1.9)</td>
<td align="left" rowspan="1" colspan="1">1.3 (0.8, 2.2)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">≥3</td>
<td align="left" rowspan="1" colspan="1"><bold>2.2 (1.4, 3.7)</bold></td>
<td align="left" rowspan="1" colspan="1">1.1 (0.7, 1.7)</td>
<td align="left" rowspan="1" colspan="1">0.9 (0.6, 1.5)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Zone</td>
<td align="left" rowspan="1" colspan="1">III</td>
<td align="left" rowspan="1" colspan="1">2.2 (0.9, 5.7)</td>
<td align="left" rowspan="1" colspan="1">2.2 (0.9, 5.2)</td>
<td align="left" rowspan="1" colspan="1">1.4 (0.6, 3.6)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">II</td>
<td align="left" rowspan="1" colspan="1"><bold>2.0 (1.3, 3.0)</bold></td>
<td align="left" rowspan="1" colspan="1">1.2 (0.8, 1.8)</td>
<td align="left" rowspan="1" colspan="1">1.2 (0.8, 1.8)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">1.5 (0.8, 3.0)</td>
<td align="left" rowspan="1" colspan="1">0.5 (0.2, 1.1)</td>
<td align="left" rowspan="1" colspan="1">0.8 (0.4, 1.5)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Plus</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">1.1 (0.7, 1.8)</td>
<td align="left" rowspan="1" colspan="1">0.8 (05, 1.4)</td>
<td align="left" rowspan="1" colspan="1">0.7 (0.4, 1.2)</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt103"><p>These have been adjusted for gestational age and birth weight Z-score. <bold>Bolded</bold> odds ratios are significant at the 0.05 level.</p></fn></table-wrap-foot></table-wrap>
<p>Males and females did not differ in nutritional intake, growth velocity, or ROP risk.</p>
</sec><sec id="s4">
<title>Discussion</title>
<p>In this cohort of extremely low gestational age newborns, intake of total calories, lipids, and carbohydrates in the lowest quartile, measured on postnatal days 3,7,14, and 21, was associated with increased risk of type 1 ROP. Similarly, infants with growth velocity in the lowest quartile were at higher risk of developing any ROP, including type 1 ROP. These findings raise the possibility that improving the early nutrition of these infants may help prevent development of sight-threatening ROP.</p>
<p>In a previous report from the ELGAN Study, the intake of protein and fat were within the generally accepted dietary goals for ELGANs, while the goals for intake of carbohydrate and total calories were not achieved. <xref ref-type="bibr" rid="pone.0064325-Martin1">[22]</xref> Controversy continues about what nutritional targets should be in preterm newborns. <xref ref-type="bibr" rid="pone.0064325-Simmer1">[32]</xref>–<xref ref-type="bibr" rid="pone.0064325-Henderson1">[36]</xref> While growth velocities were maintained above 15 mg/kg/day, most infants had a weight Z-score on day 28 that was lower than at birth. This might be viewed as an indicator of extra-uterine growth failure. Not surprisingly, infants who received protein, fat, and carbohydrate amounts in the lowest quartile on day 7 were more likely than their peers to have growth velocity in the lowest quartile. We do not know why delivery of these nutrients was suboptimal. While it is possible to observe associations between low nutrition and co-morbidities, determining whether the suboptimal delivery of nutrients contributed to development of ROP or whether co-morbidities caused the poor dietary intake is beyond the scope of information collected for this study.</p>
<p>Receipt of higher amounts of intravenous fat emulsion (2 g/kg/day; Intralipid) during the first week of life has been associated with decreased rates of ROP. <xref ref-type="bibr" rid="pone.0064325-Drenckpohl1">[9]</xref> Our observation that infants in the lowest quartile for lipid intake were at increased risk of prethreshold ROP supports this finding. The quantity but not quality of lipid intake was recorded, so it is possible that some newborns experienced lipid component deficiencies known to be important for retinal vascular development and stability, such as the omega-3 long chain polyunsaturated fatty acid docosahexaenoic acid (DHA). <xref ref-type="bibr" rid="pone.0064325-Pawlik1">[12]</xref>, <xref ref-type="bibr" rid="pone.0064325-Sapieha2">[37]</xref> Parenteral lipid supplements given in the United States do not contain DHA, and the addition of DHA to infant formula commenced near the beginning of this study period (2002). Even those who received breast milk early did not have amounts recorded or DHA concentration analyzed.</p>
<p>Poor postnatal weight gain is a predictor of severe ROP. <xref ref-type="bibr" rid="pone.0064325-Allegaert1">[14]</xref>–<xref ref-type="bibr" rid="pone.0064325-Lfqvist2">[19]</xref>, <xref ref-type="bibr" rid="pone.0064325-Binenbaum1">[38]</xref>–<xref ref-type="bibr" rid="pone.0064325-Wu2">[41]</xref> The WINROP algorithm, which measures a cumulative slowdown in weight gain, has a high sensitivity (90–100%) for detecting infants at risk of developing prethreshold ROP. A caveat to assessment of weight gain alone is the need to distinguish those infants who have non-physiologic weight gain, such as weight gain from body edema, hydrocephalus, or other causes. Infants who develop proliferative ROP often have co-morbidities such as bronchopulmonary dysplasia and necrotizing enterocolitis, which might limit nutrition and weight gain. In light of the associations between IGF-1 blood concentrations and weight gain as well as ROP risk <xref ref-type="bibr" rid="pone.0064325-Hellstrm1">[5]</xref>–<xref ref-type="bibr" rid="pone.0064325-Smith1">[8]</xref>, <xref ref-type="bibr" rid="pone.0064325-Lfqvist1">[18]</xref> it is possible that low weight gain is not in the causal chain leading to ROP, but instead is merely an indicator of IGF-1 concentration, which might be in the causal chain. While IGF-1 concentration is unlikely to influence administration of nutrients, it may influence utilization of existing nutrients.</p>
<p>Although many studies have reported low weight gain as a risk factor for ROP (<xref ref-type="table" rid="pone-0064325-t004">Table 4</xref>), and one clinical trial has assessed the contribution of intravenous fat emulsions to reducing ROP risk, this is the first observational study of suboptimal early nutrition as a risk factor for indicator of ROP severity in ELGANs. We found infants receiving the lowest quartile of lipid, carbohydrate, and total calories to be at increased risk of type 1 ROP. Higher amounts of lipid emulsion in the early days of postnatal life, in addition to DHA supplementation, could theoretically reduce ROP risk. Since higher amounts of IV lipid appear to be well tolerated, and given the importance of DHA in retina and brain development <xref ref-type="bibr" rid="pone.0064325-Connor2">[42]</xref>–<xref ref-type="bibr" rid="pone.0064325-Porcelli1">[46]</xref>, this seems to be an important nutritional component to target. Additionally, maximizing total caloric intake to support early growth appears to show promise of reducing risk of prethreshold ROP.</p>
<table-wrap id="pone-0064325-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0064325.t004</object-id><label>Table 4</label><caption>
<title>Characteristics of the eight studies that evaluated low weight gain as a risk factor for ROP.</title>
</caption><alternatives><graphic id="pone-0064325-t004-4" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0064325.t004" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Weight gain study</td>
<td align="left" rowspan="1" colspan="1">#infants</td>
<td align="left" rowspan="1" colspan="1">Entrycriteria</td>
<td align="left" rowspan="1" colspan="1">Weight analysis</td>
<td align="left" rowspan="1" colspan="1">ROP severity</td>
<td align="left" rowspan="1" colspan="1">Other risk factors<sup>∧</sup></td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Wallace et al. J AAPOS 2000</td>
<td align="left" rowspan="1" colspan="1">111</td>
<td align="left" rowspan="1" colspan="1">&lt;30 weeks</td>
<td align="left" rowspan="1" colspan="1">Relative weight gain(g/kg/d) through 6 weeks</td>
<td align="left" rowspan="1" colspan="1">&gt; stage 3</td>
<td align="left" rowspan="1" colspan="1">RBC volume transfused; bacteremia</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Allegaert et al. J AAPOS 2003</td>
<td align="left" rowspan="1" colspan="1">37</td>
<td align="left" rowspan="1" colspan="1">&lt;35 weeks or &lt;2000 g</td>
<td align="left" rowspan="1" colspan="1">Absolute weight gain(g/d) through 6 weeks</td>
<td align="left" rowspan="1" colspan="1">Threshold</td>
<td align="left" rowspan="1" colspan="1">SGA, BW &lt;25%ile</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Hellstrom et al. Pediatrics 2009</td>
<td align="left" rowspan="1" colspan="1">317</td>
<td align="left" rowspan="1" colspan="1">&lt;32 weeks</td>
<td align="left" rowspan="1" colspan="1">WINROP<xref ref-type="table-fn" rid="nt105">*</xref></td>
<td align="left" rowspan="1" colspan="1">≥ stage 3</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Fortes Filho et al. Graefes Arch Clin Exp Ophthal 2009</td>
<td align="left" rowspan="1" colspan="1">317</td>
<td align="left" rowspan="1" colspan="1">&lt;32 weeks or &lt;1500 g</td>
<td align="left" rowspan="1" colspan="1">Low weight gain(&lt;51%) at 6 weeks</td>
<td align="left" rowspan="1" colspan="1">stage 3 or threshold</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Hard et al. Arch Ophthalmol 2010</td>
<td align="left" rowspan="1" colspan="1">366</td>
<td align="left" rowspan="1" colspan="1">&lt;32 weeks</td>
<td align="left" rowspan="1" colspan="1">WINROP<xref ref-type="table-fn" rid="nt105">*</xref></td>
<td align="left" rowspan="1" colspan="1">≥ stage 3</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Wu et al. 2010 Arch Ophthalmol</td>
<td align="left" rowspan="1" colspan="1">318</td>
<td align="left" rowspan="1" colspan="1">&lt;32 weeks</td>
<td align="left" rowspan="1" colspan="1">WINROP<xref ref-type="table-fn" rid="nt105">*</xref></td>
<td align="left" rowspan="1" colspan="1">≥prethreshold or≥stage 3</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Binenbaum et al. 2011 Pediatrics</td>
<td align="left" rowspan="1" colspan="1">367</td>
<td align="left" rowspan="1" colspan="1">&lt;1000 g</td>
<td align="left" rowspan="1" colspan="1">PINT-ROP<xref ref-type="table-fn" rid="nt106">**</xref></td>
<td align="left" rowspan="1" colspan="1">&gt; stage 3 or threshold</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Wu et al. 2012 Arch Ophthalmol</td>
<td align="left" rowspan="1" colspan="1">1706</td>
<td align="left" rowspan="1" colspan="1">&lt;32 weeks</td>
<td align="left" rowspan="1" colspan="1">WINROP<xref ref-type="table-fn" rid="nt105">*</xref></td>
<td align="left" rowspan="1" colspan="1">Type 1 ROP</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">VanderVeen et al.</td>
<td align="left" rowspan="1" colspan="1">1180</td>
<td align="left" rowspan="1" colspan="1">&lt;28 weeks</td>
<td align="left" rowspan="1" colspan="1">Growth velocity between days 7 and 28<xref ref-type="table-fn" rid="nt107">***</xref></td>
<td align="left" rowspan="1" colspan="1">type 2/type 1, ≥stage 3,zone 1, plus disease</td>
<td align="left" rowspan="1" colspan="1">Birth weight Z-score; carbohydrate, protein, and lipid intake in lowest quartile</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt104"><p>∧Exclusive of birthweight and gestational age at birth.</p></fn><fn id="nt105"><label>*</label><p>Online algorithm that calculates difference between expected “safe” weight gain and actual weight gain; an alarm occurs if the accumulated values exceed a limit.<sup>15,16.</sup></p></fn><fn id="nt106"><label>**</label><p>Calculated probability of severe ROP based on risk score incorporating GA, BW, and weight gain rate (g/d).</p></fn><fn id="nt107"><label>***</label><p>[1000×((weight28-weight7)/weight7)/(28-7)] = g/kg/day.</p></fn></table-wrap-foot></table-wrap>
<p>The strengths of this study include the large number of infants studied, enrollment on the basis of well defined gestational age, a protocol with standardized assessments, and prospective collection of nutritional data. Additionally, ROP exams were performed by experienced examiners and ROP data collection occurred in a prospective and standardized fashion. Limitations include less than ideal information about dietary fat components and mode of nutrient delivery.</p>
<sec id="s4a">
<title>Conclusion</title>
<p>Low intake of lipids, carbohydrates, and total calories was associated with increased risks of sight-threatening ROP in this cohort of ELGANs. Together with previous reports that low weight gain is also a risk factor for ROP, this finding suggests that efforts to improve the nutritional intake and weight gain of the most vulnerable newborns might reduce the burden of sight-limiting ROP.</p>
</sec></sec><sec id="s5">
<title>Supporting Information</title>
<supplementary-material id="pone.0064325.s001" mimetype="application/msword" xlink:href="info:doi/10.1371/journal.pone.0064325.s001" position="float" xlink:type="simple"><label>File S1</label><caption>
<p>List of all Institutional Review Boards that approved the ELGAN study.</p>
<p>(DOC)</p>
</caption></supplementary-material></sec></body>
<back>
<ack>
<p>The authors are grateful for the contributions of ELGAN Study subjects, and their parents, as well as those of their colleagues.</p>
<p><bold>The ELGAN Study Investigators are:</bold> Baystate Medical Center, Springfield, MA: Bavesh Shah, William Seefield; Brigham &amp; Women’s Hospital, Boston, MA: Linda J. Van Marter; Massachusetts General Hospital, Boston, MA: Robert M. Insoft, Tony Fraioli; Floating Hospital for Children at Tufts Medical Center, Boston, MA: Cynthia Cole, John M. Fiascone, Caroline Baumal; U Mass Memorial Health Care, Worcester, MA: Francis Bednarek, Robert Gise; Yale University School of Medicine, New Haven, CT: Richard Ehrenkranz, Kathleen Stoessel; Wake Forest University Baptist Medical Center and Forsyth Medical Center, Winston-Salem, NC: T. Michael O’Shea, Grey Weaver; University Health System of Eastern Carolina, Greenville, NC: Stephen C. Engelke, Elaine Price Schwartz; North Carolina Children’s Hospital, Chapel Hill, NC: Carl Bose, David Wallace: Helen DeVos Children’s Hospital, Grand Rapids, MI: Mariel Poortenga, Patrick Droste; Sparrow Hospital, Lansing, MI: I. Nicholas Olomu, Linda Angell; Michigan State University, East Lansing, MI: Nigel Paneth, Padmani Karna; University of Chicago Medical Center, Chicago IL: Michael D. Schreiber, Ahmed Abdelsalam, Kourous Rezaei; William Beaumont Hospital, Royal Oak, MI: Daniel Batton, Michael Trese, Antonio Capone Jr.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0064325-Heidary1"><label>1</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Heidary</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Vanderveen</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>LE</given-names></name> (<year>2009</year>) <article-title>Retinopathy of prematurity: current concepts in molecular pathogenesis</article-title>. <source>Semin Ophthalmol</source> <volume>24(2)</volume>: <fpage>77</fpage>–<lpage>81</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Engstrm1"><label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Engström</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Niklasson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Wikland</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Ewald</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Hellström</surname><given-names>A</given-names></name> (<year>2005</year>) <article-title>The role of maternal factors, postnatal nutrition, weight gain, and gender in regulation of serum IGF-I among preterm infants</article-title>. <source>Pediatr Res</source> <volume>57(4)</volume>: <fpage>605</fpage>–<lpage>610</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Lo1"><label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lo</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Tsao</surname><given-names>LY</given-names></name>, <name name-style="western"><surname>Hsu</surname><given-names>WY</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>HN</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>WK</given-names></name>, <etal>et al</etal>. (<year>2002</year>) <article-title>Relation of cord serum levels of growth hormone, insulin-like growth factors, insulin-like growth factor binding proteins, leptin, and interleukin-6 with birth weight, birth length, and head circumference in term and preterm neonates</article-title>. <source>Nutrition</source> <volume>18(7–8)</volume>: <fpage>604</fpage>–<lpage>608</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Pirazzoli1"><label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pirazzoli</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Cacciari</surname><given-names>E</given-names></name>, <name name-style="western"><surname>De Iasio</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Pittalis</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Dallacasa</surname><given-names>P</given-names></name>, <etal>et al</etal>. (<year>1997</year>) <article-title>Developmental pattern of fetal growth hormone, insulin-like growth factor I, growth hormone binding protein and insulin-like growth factor binding protein-3</article-title>. <source>Arch Dis Child Fetal Neonatal Ed</source><volume>77</volume><supplement>(2)</supplement>: <fpage>F100</fpage>–<lpage>104</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Hellstrm1"><label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hellström</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Engström</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hård</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Albertsson-Wikland</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Carlsson</surname><given-names>B</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth</article-title>. <source>Pediatrics</source> <volume>112(5)</volume>: <fpage>1016</fpage>–<lpage>1020</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Hellstrm2"><label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hellström</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Perruzzi</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ju</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Engström</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hård</surname><given-names>AL</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>98(10)</volume>: <fpage>5804</fpage>–<lpage>5808</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Hikino1"><label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hikino</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ihara</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Takahata</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Nakayama</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>Physical growth and retinopathy in preterm infants: involvement of IGF-I and GH</article-title>. <source>Pediatr Res</source> <volume>50(6)</volume>: <fpage>732</fpage>–<lpage>736</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Smith1"><label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Smith</surname><given-names>LE</given-names></name> (<year>2005</year>) <article-title>IGF-1 and retinopathy of prematurity in the preterm infant</article-title>. <source>Biol Neonate</source> <volume>88(3)</volume>: <fpage>237</fpage>–<lpage>244</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Drenckpohl1"><label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Drenckpohl</surname><given-names>D</given-names></name>, <name name-style="western"><surname>McConnell</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Gaffney</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Niehaus</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Macwan</surname><given-names>KS</given-names></name> (<year>2008</year>) <article-title>Randomized trial of very low birth weight infants receiving higher rates of infusion of intravenous fat emulsions during the first week of life</article-title>. <source>Pediatrics</source> <volume>122(4)</volume>: <fpage>743</fpage>–<lpage>751</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-SanGiovanni1"><label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>SanGiovanni</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Chew</surname><given-names>EY</given-names></name> (<year>2005</year>) <article-title>The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina</article-title>. <source>Prog Retin Eye Res</source> <volume>24(1)</volume>: <fpage>87</fpage>–<lpage>138</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Sapieha1"><label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sapieha</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Joyal</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Rivera</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Kermorvant-Duchemin</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Sennlaub</surname><given-names>F</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life</article-title>. <source>J Clin Invest</source> <volume>120(9)</volume>: <fpage>3022</fpage>–<lpage>3032</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Pawlik1"><label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pawlik</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lauterbach</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Turyk</surname><given-names>E</given-names></name> (<year>2011</year>) <article-title>Fish-oil fat emulsion supplementation may reduce the risk of severe retinopathy in VLBW infants</article-title>. <source>Pediatrics</source> <volume>127(2)</volume>: <fpage>223</fpage>–<lpage>228</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Connor1"><label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Connor</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>SanGiovanni</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Löfqvist</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Aderman</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med</article-title>. <volume>13(7)</volume>: <fpage>868</fpage>–<lpage>873</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Allegaert1"><label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Allegaert</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Vanhole</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Casteels</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Naulaers</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Debeer</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Perinatal growth characteristics and associated risk of developing threshold retinopathy of prematurity</article-title>. <source>J AAPOS</source> <volume>7(1)</volume>: <fpage>34</fpage>–<lpage>37</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Wallace1"><label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wallace</surname><given-names>DK</given-names></name>, <name name-style="western"><surname>Kylstra</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Phillips</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Hall</surname><given-names>JG</given-names></name> (<year>2000</year>) <article-title>Poor postnatal weight gain: a risk factor for severe retinopathy of prematurity. J AAPOS</article-title>. <volume>4(6)</volume>: <fpage>343</fpage>–<lpage>347</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Hellstrm3"><label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hellström</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hård</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Engström</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Niklasson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Andersson</surname><given-names>E</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Early weight gain predicts retinopathy in preterm infants: new, simple, efficient approach to screening</article-title>. <source>Pediatrics</source> <volume>123(4)</volume>: <fpage>e638</fpage>–<lpage>645</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-FortesFilho1"><label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fortes Filho</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Bonomo</surname><given-names>PP</given-names></name>, <name name-style="western"><surname>Maia</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Procianoy</surname><given-names>RS</given-names></name> (<year>2009</year>) <article-title>Weight gain measured at 6 weeks after birth as a predictor for severe retinopathy of prematurity: study with 317 very low birth weight preterm babies</article-title>. <source>Graefes Arch Clin Exp Ophthalmol</source> <volume>247(6)</volume>: <fpage>831</fpage>–<lpage>836</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Lfqvist1"><label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Löfqvist</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hansen-Pupp</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Andersson</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Holm</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>LE</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Validation of a new retinopathy of prematurity screening method monitoring longitudinal postnatal weight and insulinlike growth factor I. Arch Ophthalmol</article-title>. <volume>127(5)</volume>: <fpage>622</fpage>–<lpage>627</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Lfqvist2"><label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Löfqvist</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Andersson</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Sigurdsson</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Engström</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hård</surname><given-names>AL</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity</article-title>. <source>Arch Ophthalmol</source> <volume>124(12)</volume>: <fpage>1711</fpage>–<lpage>1718</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-OShea1"><label>20</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>O’Shea</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Allred</surname><given-names>EN</given-names></name>, <name name-style="western"><surname>Dammann</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Hirtz</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kuban</surname><given-names>KC</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>The ELGAN study of the brain and related disorders in extremely low gestational age newborns</article-title>. <source>Early Hum Dev</source> <volume>85(11)</volume>: <fpage>719</fpage>–<lpage>725</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Chen1"><label>21</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Allred</surname><given-names>EN</given-names></name>, <name name-style="western"><surname>Hecht</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Onderdonk</surname><given-names>A</given-names></name>, <name name-style="western"><surname>VanderVeen</surname><given-names>D</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Placenta Microbiology and Histology, and The Risk for Severe Retinopathy of Prematurity. Invest Ophthalmol Vis Sci</article-title>. <volume>52(10)</volume>: <fpage>7052</fpage>–<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Martin1"><label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Martin</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>YF</given-names></name>, <name name-style="western"><surname>Ehrenkranz</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>O’Shea</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Allred</surname><given-names>EN</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Nutritional practices and growth velocity in the first month of life in extremely premature infants</article-title>. <source>Pediatrics</source> <volume>124(2)</volume>: <fpage>649</fpage>–<lpage>657</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Ehrenkranz1"><label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ehrenkranz</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Younes</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Lemons</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Fanaroff</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Donovan</surname><given-names>EF</given-names></name>, <etal>et al</etal>. (<year>1999</year>) <article-title>Longitudinal growth of hospitalized very low birth weight infants</article-title>. <source>Pediatrics 104(2 Pt</source> <volume>1)</volume>: <fpage>280</fpage>–<lpage>289</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-The1"><label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple"><collab xlink:type="simple">The Committee for the Classification of Retinopathy of Prematurity</collab> (<year>1984</year>) <article-title>An international classification of retinopathy of prematurity</article-title>. <source>Arch Ophthalmol</source> <volume>102(8)</volume>: <fpage>1130</fpage>–<lpage>1134</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Screeningexaminationofprematureinfantsforretinopathyof1"><label>25</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Screening examination of premature infants for retinopathy of</surname><given-names>prematurity</given-names></name> (<year>2001</year>) <article-title>Pediatrics</article-title>. <volume>108(3)</volume>: <fpage>809</fpage>–<lpage>811</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Screeningexaminationofprematureinfantsforretinopathyof2"><label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Screening examination of premature infants for retinopathy of</surname><given-names>prematurity</given-names></name> (<year>2013</year>) <article-title>Pediatrics</article-title>. <volume>131</volume>: <fpage>189</fpage>–<lpage>195</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Early1"><label>27</label>
<mixed-citation publication-type="other" xlink:type="simple">Early Treatment For Retinopathy Of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121(12): 1684–1694.Begg MD, Parides MK (2003).</mixed-citation>
</ref>
<ref id="pone.0064325-Fielder1"><label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fielder</surname><given-names>AR</given-names></name> (<year>2003</year>) <article-title>Preliminary results of treatment of eyes with high-risk prethreshold retinopathy of prematurity in the early treatment for retinopathy of prematurity randomized trial</article-title>. <source>Arch Ophthalmol</source> <volume>121(12)</volume>: <fpage>1769</fpage>–<lpage>1771</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Begg1"><label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Parides</surname><given-names>MK</given-names></name> (<year>2003</year>) <article-title>Separation of individual-level and cluster-level covariate effects in regression analysis of correlated data</article-title>. <source>Stat Med</source> <volume>22(16)</volume>: <fpage>2591</fpage>–<lpage>2602</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Dubin1"><label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dubin</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Pasternack</surname><given-names>BS</given-names></name> (<year>1986</year>) <article-title>Risk assessment for case-control subgroups by polychotomous logistic regression</article-title>. <source>Am J Epidemiol</source> <volume>123(6)</volume>: <fpage>1101</fpage>–<lpage>1117</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Liang1"><label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liang</surname><given-names>KY</given-names></name>, <name name-style="western"><surname>Zeger</surname><given-names>S</given-names></name> (<year>1986</year>) <article-title>Longitudinal data analysis using generalized linear models</article-title>. <source>Biometrika</source> <volume>73</volume>: <fpage>13</fpage>–<lpage>22</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Simmer1"><label>32</label>
<mixed-citation publication-type="other" xlink:type="simple">Simmer K, Rao SC (2005) Early introduction of lipids to parenterally-fed preterm infants. Cochrane Database Syst Rev CD005256.</mixed-citation>
</ref>
<ref id="pone.0064325-Premji1"><label>33</label>
<mixed-citation publication-type="other" xlink:type="simple">Premji SS, Fenton TR, Sauve RS (2006) Higher versus lower protein intake in formula-fed low birth weight infants. Cochrane Database Syst Rev CD003959.</mixed-citation>
</ref>
<ref id="pone.0064325-Premji2"><label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Premji</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fenton</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Sauve</surname><given-names>R</given-names></name> (<year>2006</year>) <article-title>Does amount of protein in formula matter for low-birthweight infants? A Cochrane systematic review</article-title>. <source>JPEN J Parenter Enteral Nutr</source> <volume>30(6)</volume>: <fpage>507</fpage>–<lpage>514</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-KlenoffBrumberg1"><label>35</label>
<mixed-citation publication-type="other" xlink:type="simple">Klenoff-Brumberg HL, Genen LH (2003) High versus low medium chain triglyceride content of formula for promoting short term growth of preterm infants. Cochrane Database Syst Rev CD002777.</mixed-citation>
</ref>
<ref id="pone.0064325-Henderson1"><label>36</label>
<mixed-citation publication-type="other" xlink:type="simple">Henderson G, Fahey T, McGuire W (2005) Calorie and protein-enriched formula versus standard term formula for improving growth and development in preterm or low birth weight infants following hospital discharge. Cochrane Database Syst Rev CD004696.</mixed-citation>
</ref>
<ref id="pone.0064325-Sapieha2"><label>37</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sapieha</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Stahl</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Seaward</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Willett</surname><given-names>KL</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of omega-3 polyunsaturated fatty acids</article-title>. <source>Sci Transl Med</source> <volume>3(69)</volume>: <fpage>69ra12</fpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Binenbaum1"><label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Binenbaum</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ying</surname><given-names>GS</given-names></name>, <name name-style="western"><surname>Quinn</surname><given-names>GE</given-names></name>, <name name-style="western"><surname>Dreiseitl</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Karp</surname><given-names>K</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>A clinical prediction model to stratify retinopathy of prematurity risk using postnatal weight gain</article-title>. <source>Pediatrics</source> <volume>127(3)</volume>: <fpage>e607</fpage>–<lpage>614</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Wu1"><label>39</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Vanderveen</surname><given-names>DK</given-names></name>, <name name-style="western"><surname>Hellström</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Löfqvist</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>LE</given-names></name> (<year>2010</year>) <article-title>Longitudinal postnatal weight measurements for the prediction of retinopathy of prematurity</article-title>. <source>Arch Ophthalmol</source> <volume>128(4)</volume>: <fpage>443</fpage>–<lpage>447</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Hrd1"><label>40</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hård</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Löfqvist</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Fortes Filho</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Procianoy</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>L</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Predicting proliferative retinopathy in a Brazilian population of preterm infants with the screening algorithm WINROP</article-title>. <source>Arch Ophthalmol</source> <volume>128(11)</volume>: <fpage>1432</fpage>–<lpage>1436</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Wu2"><label>41</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Löfqvist</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>LE</given-names></name>, <name name-style="western"><surname>VanderVeen</surname><given-names>DK</given-names></name>, <name name-style="western"><surname>Hellström</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Importance of early postnatal weight gain for normal retinal angiogenesis in very preterm infants: a multicenter study analyzing weight velocity deviations for the prediction of retinopathy of prematurity</article-title>. <source>Arch Ophthalmol</source> <volume>130(8)</volume>: <fpage>992</fpage>–<lpage>9</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Connor2"><label>42</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Connor</surname><given-names>WE</given-names></name>, <name name-style="western"><surname>Neuringer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Reisbick</surname><given-names>S</given-names></name> (<year>1992</year>) <article-title>Essential fatty acids: the importance of n-3 fatty acids in the retina and brain</article-title>. <source>Nutr Rev 50(4 (Pt</source> <volume>2))</volume>: <fpage>21</fpage>–<lpage>29</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Lucas1"><label>43</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lucas</surname><given-names>A</given-names></name>, <name name-style="western"><surname>King</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Bishop</surname><given-names>NB</given-names></name> (<year>1992</year>) <article-title>Postdischarge formula consumption in infants born preterm</article-title>. <source>Arch Dis Child</source> <volume>67(6)</volume>: <fpage>691</fpage>–<lpage>692</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Lucas2"><label>44</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lucas</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bishop</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>King</surname><given-names>FJ</given-names></name>, <name name-style="western"><surname>Cole</surname><given-names>TJ</given-names></name> (<year>1992</year>) <article-title>Randomised trial of nutrition for preterm infants after discharge</article-title>. <source>Arch Dis Child</source> <volume>67(3)</volume>: <fpage>324</fpage>–<lpage>327</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Furman1"><label>45</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Furman</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Minich</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Hack</surname><given-names>M</given-names></name> (<year>2003</year>) <article-title>The effect of maternal milk on neonatal morbidity of very low-birth-weight infants</article-title>. <source>Arch Pediatr Adolesc Med</source> <volume>157(1)</volume>: <fpage>66</fpage>–<lpage>71</lpage>.</mixed-citation>
</ref>
<ref id="pone.0064325-Porcelli1"><label>46</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Porcelli</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Weaver</surname><given-names>RG</given-names><suffix>Jr</suffix></name> (<year>2010</year>) <article-title>The influence of early postnatal nutrition on retinopathy of prematurity in extremely low birth weight infants</article-title>. <source>Early Hum Dev</source> <volume>86(6)</volume>: <fpage>391</fpage>–<lpage>6</lpage>.</mixed-citation>
</ref>
</ref-list></back>
</article>